These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 8390259)

  • 1. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
    Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
    Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
    Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
    Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
    Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
    de Jong S; Zijlstra JG; Mulder NH; de Vries EG
    Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
    Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
    Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
    Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
    Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16.
    Petersen LN; Jensen PB; Sørensen BS; Engelholm SA; Spang-Thomsen M
    Invest New Drugs; 1994; 12(4):289-97. PubMed ID: 7775129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.
    Smith PJ; Morgan SA; Fox ME; Watson JV
    Biochem Pharmacol; 1990 Nov; 40(9):2069-78. PubMed ID: 2173600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
    Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
    Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
    De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
    Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.
    Capranico G; Supino R; Binaschi M; Capolongo L; Grandi M; Suarato A; Zunino F
    Mol Pharmacol; 1994 May; 45(5):908-15. PubMed ID: 8190107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M; Beck WT
    Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
    Zunino F; Capranico G
    Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor.
    Hajji N; Mateos S; Pastor N; Domínguez I; Cortés F
    Mutat Res; 2005 May; 583(1):26-35. PubMed ID: 15866463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
    Pawlik CA; Israel M; Sweatman TW; Lothstein L
    Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.